Weekly Evolocumab Therapy for Prevention of Recurrent Hypertriglyceridemia-Induced Pancreatitis: A Case Report

Hypertriglyceridemia-induced pancreatitis is the third most common cause of acute pancreatitis and is often severe. We describe a case of a woman in her 60s with familial hypertriglyceridemia who suffered four pancreatitis episodes within 14 months despite treatment with fibrates, niacin, omega-3 fatty acids, statins, and icosapent ethyl. Presenting triglycerides were 39.2 to 45.7 mmol/L in three episodes and 13.5 mmol/L in the fourth. She declined plasmapheresis; volanesorsen was unavailable. Off-label evolocumab 140 mg was initiated subcutaneously. Triglycerides fell 30 to 40% within 2 to 3 days of each injection (for example, from 25.4 to 17.9 mmol/L) and rose back toward baseline by day 7. She was therefore transitioned to weekly rather than the standard biweekly dosing. Over the first 12 weeks, triglycerides ranged from 13.5 to 36.0 mmol/L (median: 19.0). At 12 months, she remained pancreatitis-free without adverse effects. Weekly evolocumab may benefit selected patients with treatment-resistant hypertriglyceridemia.

Authors

Institutions

Publication Details

Journal
Avicenna Journal of Medicine
Published
2026-11-18
DOI
https://doi.org/10.1055/s-0046-1829901
Primary Topic
Pancreatitis Pathology and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Weekly Evolocumab Therapy for Prevention of Recurrent Hypertriglyceridemia-Induced Pancreatitis: A Case Report

Mohamed Madani Alfagi, Fahad Wali Ahmed, Sana Javed, Sagheer Ahmed et al.
4 links
Avicenna Journal of Medicine
Pancreatitis Pathology and Treatment
article

Weekly Evolocumab Therapy for Prevention of Recurrent Hypertriglyceridemia-Induced Pancreatitis: A Case Report

Mohamed Madani Alfagi, Fahad Wali Ahmed, Sana Javed, Sagheer Ahmed, Mubashar Sultan Kharal
article en

Abstract

Hypertriglyceridemia-induced pancreatitis is the third most common cause of acute pancreatitis and is often severe. We describe a case of a woman in her 60s with familial hypertriglyceridemia who suffered four pancreatitis episodes within 14 months despite treatment with fibrates, niacin, omega-3 fatty acids, statins, and icosapent ethyl. Presenting triglycerides were 39.2 to 45.7 mmol/L in three episodes and 13.5 mmol/L in the fourth. She declined plasmapheresis; volanesorsen was unavailable. Off-label evolocumab 140 mg was initiated subcutaneously. Triglycerides fell 30 to 40% within 2 to 3 days of each injection (for example, from 25.4 to 17.9 mmol/L) and rose back toward baseline by day 7. She was therefore transitioned to weekly rather than the standard biweekly dosing. Over the first 12 weeks, triglycerides ranged from 13.5 to 36.0 mmol/L (median: 19.0). At 12 months, she remained pancreatitis-free without adverse effects. Weekly evolocumab may benefit selected patients with treatment-resistant hypertriglyceridemia.

Avicenna Journal of Medicine
King Faisal Specialist Hospital & Research Centre (SA)
Good health and well-being
Pancreatitis Pathology and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon